ѻýҕl

FreeStyle Libre 3 Sensor Class I Recall; Second OTC CGM Cleared; Weekly Insulin Win

<ѻýҕl class="mpt-content-deck">— News and commentary from the endocrinology world
Last Updated September 10, 2024
MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

The FDA designated Abbott's as the most serious, class I type due to the risk for incorrect high glucose readings.

After parts of her large intestine died and needed to be removed, a patient , claiming the label of semaglutide (Ozempic, Wegovy) didn't adequately warn about serious side effects. (CBS News)

A demonstrated comparable efficacy and safety to branded Prolia in a phase III study of women with postmenopausal osteoporosis. (Journal of Clinical Endocrinology & Metabolism)

Abbott launched an over-the-counter , Lingo, for adults not on insulin -- the second such device to hit the market.

The on ersodetug, a possible treatment for hypoglycemia caused by congenital hyperinsulinism being studied in a phase III trial, said developer Rezolute.

In a phase I dose-finding study of people with overweight or obesity, the highest dose of investigational yielded a 4.9% placebo-adjusted weight loss over 28 days, said developer Terns Pharmaceuticals.

Modular Medical said the FDA cleared its for all adults with type 1 and 2 diabetes.

The agency also cleared Embecta's with a 300-unit insulin reservoir for people with type 2 diabetes.

Exposure to particulate matter with a diameter less than 2.5 µm was in Danish men ages 30 to 45. (BMJ)

Once-weekly had non-inferior HbA1c reduction compared with daily insulin glargine or insulin degludec (Tresiba) over 52 weeks in adults with type 2 diabetes, according to the QWINT-1 and -3 trials, respectively. Developer Eli Lilly will release results from the QWINT-2 and -5 trials at this week's European Association for the Study of Diabetes (EASD) annual meeting.

Here's how to spot . (Reuters)

Some patients with obesity aren't receiving when doctors say the procedures are too risky due to their weight. (New York Times)

SGLT2 inhibitors added to standard-of-care for 30 days didn't increase days free of organ support or reduce mortality in , the ACTIV-4a trial found. (Lancet Diabetes & Endocrinology)

Nonsteroidal anti-inflammatory drugs (NSAIDs) were the in acute osteoporotic vertebral compression fractures, a 20-trial meta-analysis found. (JAMA Network Open)

Women exposed to higher levels of certain per- and polyfluoroalkyl substances (PFAS) early in pregnancy had around age 51. (Journal of Clinical Endocrinology & Metabolism)

Britain's healthcare regulator of being linked with suicidal thoughts, in line with conclusions from a European regulatory review and preliminary findings from the FDA.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.